The Trump administration on Friday announced deals with nine drugmakers aimed at lowering pharmaceutical prices, bringing its total number of drug-pricing agreements to 14.
The $6 billion deal between Trump's social media and cryptocurrency company and TAE Technologies aimed at bringing fusion energy to the market raises conflict of interest questions.
